髄膜炎菌ワクチン市場：タイプ別、カテゴリー別、用量タイプ別、ターゲットグループ別、エンドユーザー別-2025-2030年世界予測

髄膜炎菌ワクチン市場の2023年の市場規模は54億5,000万米ドルで、2024年には59億5,000万米ドルに達すると予測され、CAGR 10.50％で成長し、2030年には109億7,000万米ドルに達すると予測されています。

髄膜炎菌ワクチン市場の範囲は、主に青少年と若年成人、および特定のハイリスクグループを対象とした、髄膜炎菌による感染症を予防するためのワクチンの生産と展開です。その必要性は、髄膜炎や敗血症などの壊滅的な結果をもたらす髄膜炎菌感染症がもたらす深刻な健康上の脅威から生じています。これらのワクチンは主に公衆衛生の予防接種戦略で使用され、流行しやすい地域や特定の健康リスクを持つ人に特に推奨されています。最終用途には、ヘルスケアプロバイダー、診療所、政府保健機関、研究機関などが含まれます。主な成長促進要因としては、予防接種プログラムに対する政府の関心の高まり、病気のリスクに対する意識の高まり、ワクチン製剤の技術的進歩などが挙げられます。特筆すべきは、COVID-19の大流行によってワクチン接種の重要性が強化され、間接的に投資と認知度が高まったことで、市場関係者には支援活動や教育活動を拡大する機会がもたらされたことです。現在のビジネスチャンスとしては、疾病負担の大きい新興諸国向けに、より安価で入手しやすいワクチンの開発や、ワクチンの保管・供給技術の革新などが挙げられます。しかし、低所得地域ではワクチン接種へのためらい、規制上のハードル、物流の障壁といった課題があり、市場拡大の足かせとなっています。さらに、より広範な感染症領域における他の生物学的製剤や予防治療との競合は、市場の飽和リスクをもたらします。技術革新の主なポイントは、ワクチンの有効性の向上、血清群のカバー範囲の拡大、注射針を使用しない選択肢などの送達メカニズムの改善です。個別化医療やmRNAベースのワクチンに対する動向も高まっており、市場はこの動向を探ることができます。市場情勢は、有望でありながら複雑な動きを見せており、研究への投資や公衆衛生機関との協力といった戦略的な支援活動とバランスを取りながら、世界の予防接種の状況における新たな機会を活用し、内在する限界を克服する必要があります。

市場力学：急速に進化する髄膜炎菌ワクチン市場の主要市場インサイトを公開

髄膜炎菌ワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で増加する髄膜炎の発生率
  • 研究開発活動の活発化とパイプラインにおけるワクチン開発
  • 髄膜炎菌疾患に対する予防接種プログラムおよび政府の取り組みの増加
• 市場抑制要因
  • 生産コストの高さ
• 市場機会
  • 新興国における細菌性髄膜炎の発生率とサーベイランスシステムの改善
  • ワクチン開発を支援する共同研究やパートナーシップの強化
• 市場の課題
  • 髄膜炎菌ワクチンに関連する限界と副作用

ポーターの5つの力：髄膜炎菌ワクチン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：髄膜炎菌ワクチン市場における外部からの影響の把握

外部マクロ環境要因は、髄膜炎菌ワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析髄膜炎菌ワクチン市場における競合情勢の把握

髄膜炎菌ワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス髄膜炎菌ワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、髄膜炎菌ワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨髄膜炎菌ワクチン市場における成功への道筋を描く

髄膜炎菌ワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で髄膜炎の発生率が増加
    • 研究開発活動の増加とパイプライン内のワクチン開発
    • 髄膜炎菌感染症に対する予防接種プログラムと政府の取り組みの増加
  • 抑制要因
    • 髄膜炎菌ワクチン制作コストが高い
  • 機会
    • 新興国における細菌性髄膜炎の発生率と監視システムの改善
    • ワクチン開発を支援するための協力とパートナーシップの強化
  • 課題
    • 髄膜炎菌ワクチンに関連する制限と副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 髄膜炎菌ワクチン市場：タイプ別

• 混合ワクチン
  • メンハイブリックス
  • メニトリックス
• 結合ワクチン
  • メナクトラ
  • メンアフリヴァック
  • メニンギテック
  • メンジュガテ
  • メンベオ
  • ネイスバックC
  • ニメンリックス
  • NmVac4-DT
• メンBワクチン
  • ベクセロ
  • トルメンバ
• 多糖類ワクチン
  • メンセヴァクス
  • メノムネ
  • ＮｍＶａｃ４

第7章 髄膜炎菌ワクチン市場：カテゴリ別

• 筋肉内
• 皮下

第8章 髄膜炎菌ワクチン市場投与量タイプ別

• 追加接種
• 一次ワクチン接種

第9章 髄膜炎菌ワクチン市場ターゲットグループ別

• 成人用
• プレティーン
• ティーンエイジャー

第10章 髄膜炎菌ワクチン市場：エンドユーザー別

• 病院薬局
• 小児科クリニック
• 小売薬局

第11章 南北アメリカの髄膜炎菌ワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の髄膜炎菌ワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの髄膜炎菌ワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Astellas Pharma Inc.
• AstraZeneca PLC
• Bavarian Nordic A/S
• Bharat Biotech Ltd.
• Bio-Manguinhos
• Bio-Med（P）Limited
• CanSino Biologics Inc.
• Chongqing Zhifei Biological Products Co., Ltd.
• Emergent BioSolutions Inc.
• GlaxoSmithKline PLC
• Incepta Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Nanolek, LLC
• Novartis AG
• Panacea Biotec Ltd.
• Petrovax Pharm
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Shanghai Fosun Pharmaceutical（Group）Co., Ltd.
• Sinovac Biotech Ltd.
• SK bioscience
• Taj Pharmaceuticals Limited
• Vabiotech
• Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

• FIGURE 1. MENINGOCOCCAL VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. MENINGOCOCCAL VACCINES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MENINGOCOCCAL VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MENINGOCOCCAL VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENHIBRIX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENITORIX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENACTRA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENAFRIVAC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENINGITEC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENJUGATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENVEO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY NEISVAC-C, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY NIMENRIX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY NMVAC4-DT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY BEXSERO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRUMENBA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENCEVAX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENOMUNE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY NMVAC4, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY BOOSTER VACCINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PRIMARY VACCINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PRETEEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TEENAGER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC CLINIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 75. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 76. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 77. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 78. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 79. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 81. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 104. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 105. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 106. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 111. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 113. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 114. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 115. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 116. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 117. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 122. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 123. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 124. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 125. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 126. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 128. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 131. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 132. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 133. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 134. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 135. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 136. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 137. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 140. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 141. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 142. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 143. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 144. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 146. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 149. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 150. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 151. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 152. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 153. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 154. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 155. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 158. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 159. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 160. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 161. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 162. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 163. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 164. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 167. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 168. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 169. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 170. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 171. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 172. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 173. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 176. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 177. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 178. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 179. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 180. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 181. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 182. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 185. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 186. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 187. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 188. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 189. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 190. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 191. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 192. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 194. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 195. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 196. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 197. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 198. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 199. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 200. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 202. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 203. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 204. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 205. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 206. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 207. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 208. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 209. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 210. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 211. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 212. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 213. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 214. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 215. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 216. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 217. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 218. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 227. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 229. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 230. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 231. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 232. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 233. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 234. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 235. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 236. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 237. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 238. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 239. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 240. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 241. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 242. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 243. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 244. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 245. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 246. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 247. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 248. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 249. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 250. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 251. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 252. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 253. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 254. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 255. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 256. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 257. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 258. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 259. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 260. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 261. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 262. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 263. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 264. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 265. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 266. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 267. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 268. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 269. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 270. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 271. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 272. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 273. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 274. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 275. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 276. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 277. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 278. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 279. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 280. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 281. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 282. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 283. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 284. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 285. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 286. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 287. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 288. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 289. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 290. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 291. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 292. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 293. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 294. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 295. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 296. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 297. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 298. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 299. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 300. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 301. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 302. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 303. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 304. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 305. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 306. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 307. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 308. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 309. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 310. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 311. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 312. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 313. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 314. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 315. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 316. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 317. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 318. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 319. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 320. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 321. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 322. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 323. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 324. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 325. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 326. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
• TABLE 327. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 328. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 329. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 330. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
• TABLE 331. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
• TABLE 332. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
• TABLE 333. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 334. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
• TABLE 335. QATAR MENINGOC

The Meningococcal Vaccines Market was valued at USD 5.45 billion in 2023, expected to reach USD 5.95 billion in 2024, and is projected to grow at a CAGR of 10.50%, to USD 10.97 billion by 2030.

The scope of the meningococcal vaccines market entails production and deployment of vaccines designed to prevent infections caused by Neisseria meningitidis, targeting primarily adolescents and young adults as well as certain high-risk groups. The necessity arises from the serious health threat posed by meningococcal disease, which can result in devastating outcomes such as meningitis and septicemia. These vaccines are employed primarily in public health immunization strategies and are specifically recommended in outbreak-prone regions and for individuals with specific health risks. The end-use scope encompasses healthcare providers, clinics, governmental health organizations, and research institutions. Key growth drivers include heightened government focus on immunization programs, rising awareness about the disease's risks, and technological advancements in vaccine formulations. Notably, the COVID-19 pandemic reinforced the importance of vaccination, indirectly boosting investments and awareness, presenting opportunities for market players to expand outreach and educational efforts. Current opportunities include developing more affordable and accessible vaccine options for developing countries, where disease burden is often higher, as well as innovations in vaccine storage and delivery technologies. However, challenges such as vaccine hesitancy, regulatory hurdles, and logistical barriers in low-income regions stifle market expansion. Additionally, the competition from other biologic and preventive treatments in broader infectious disease domains presents market saturation risks. Innovations largely lie in enhancing vaccine efficacy, broadening serogroup coverage, and improving delivery mechanisms, such as needle-free options. There is a rising trend towards personalized medicine and mRNA-based vaccines, which the market can explore. The meningococcal vaccines market showcases a promising yet complex dynamic that requires balancing strategic outreach with investment in research and collaboration with public health entities to overcome inherent limitations while capitalizing on emerging opportunities in the global immunization landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Meningococcal Vaccines Market

The Meningococcal Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing Incidence of Meningitis Across the World
  • Rising R&D Activities and Vaccines Developments in the Pipeline
  • Rising Immunization Programs and Government Initiatives for Meningococcal Diseases
• Market Restraints
  • High Cost of Meningococcal Vaccines Production
• Market Opportunities
  • Incidence of Bacterial Meningitis in Emerging Countries Coupled with Improvement in Surveillance System
  • Elevation of Collaborations and Partnerships to Support the Development of the Vaccines
• Market Challenges
  • Limitations and Side Effects Associated with Meningococcal Vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Meningococcal Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Meningococcal Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Meningococcal Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Meningococcal Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Meningococcal Vaccines Market

A detailed market share analysis in the Meningococcal Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Meningococcal Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Meningococcal Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Meningococcal Vaccines Market

A strategic analysis of the Meningococcal Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Meningococcal Vaccines Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Bio-Manguinhos, Bio-Med (P) Limited, CanSino Biologics Inc., Chongqing Zhifei Biological Products Co., Ltd., Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Pharmaceuticals Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Nanolek, LLC, Novartis AG, Panacea Biotec Ltd., Petrovax Pharm, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Sinovac Biotech Ltd., SK bioscience, Taj Pharmaceuticals Limited, Vabiotech, and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Meningococcal Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Combination Vaccines, Conjugate Vaccines, Men B Vaccines, and Polysaccharide Vaccines. The Combination Vaccines is further studied across MenHibrix and Menitorix. The Conjugate Vaccines is further studied across Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, and NmVac4-DT. The Men B Vaccines is further studied across Bexsero and Trumenba. The Polysaccharide Vaccines is further studied across Mencevax, Menomune, and NmVac4.
• Based on Category, market is studied across Intramuscular and Subcutaneous.
• Based on Dosage Type, market is studied across Booster Vaccination and Primary Vaccination.
• Based on Target Group, market is studied across Adult, Preteen, and Teenager.
• Based on End-User, market is studied across Hospital Pharmacies, Pediatric Clinic, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Incidence of Meningitis Across the World
    • 5.1.1.2. Rising R&D Activities and Vaccines Developments in the Pipeline
    • 5.1.1.3. Rising Immunization Programs and Government Initiatives for Meningococcal Diseases
  • 5.1.2. Restraints
    • 5.1.2.1. High Cost of Meningococcal Vaccines Production
  • 5.1.3. Opportunities
    • 5.1.3.1. Incidence of Bacterial Meningitis in Emerging Countries Coupled with Improvement in Surveillance System
    • 5.1.3.2. Elevation of Collaborations and Partnerships to Support the Development of the Vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations and Side Effects Associated with Meningococcal Vaccines
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Meningococcal Vaccines Market, by Type

• 6.1. Introduction
• 6.2. Combination Vaccines
  • 6.2.1. MenHibrix
  • 6.2.2. Menitorix
• 6.3. Conjugate Vaccines
  • 6.3.1. Menactra
  • 6.3.2. MenAfriVac
  • 6.3.3. Meningitec
  • 6.3.4. Menjugate
  • 6.3.5. Menveo
  • 6.3.6. NeisVac-C
  • 6.3.7. Nimenrix
  • 6.3.8. NmVac4-DT
• 6.4. Men B Vaccines
  • 6.4.1. Bexsero
  • 6.4.2. Trumenba
• 6.5. Polysaccharide Vaccines
  • 6.5.1. Mencevax
  • 6.5.2. Menomune
  • 6.5.3. NmVac4

7. Meningococcal Vaccines Market, by Category

• 7.1. Introduction
• 7.2. Intramuscular
• 7.3. Subcutaneous

8. Meningococcal Vaccines Market, by Dosage Type

• 8.1. Introduction
• 8.2. Booster Vaccination
• 8.3. Primary Vaccination

9. Meningococcal Vaccines Market, by Target Group

• 9.1. Introduction
• 9.2. Adult
• 9.3. Preteen
• 9.4. Teenager

10. Meningococcal Vaccines Market, by End-User

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Pediatric Clinic
• 10.4. Retail Pharmacies

11. Americas Meningococcal Vaccines Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Meningococcal Vaccines Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Meningococcal Vaccines Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Astellas Pharma Inc.
• 2. AstraZeneca PLC
• 3. Bavarian Nordic A/S
• 4. Bharat Biotech Ltd.
• 5. Bio-Manguinhos
• 6. Bio-Med (P) Limited
• 7. CanSino Biologics Inc.
• 8. Chongqing Zhifei Biological Products Co., Ltd.
• 9. Emergent BioSolutions Inc.
• 10. GlaxoSmithKline PLC
• 11. Incepta Pharmaceuticals Ltd.
• 12. Merck & Co., Inc.
• 13. Mitsubishi Tanabe Pharma Corporation
• 14. Nanolek, LLC
• 15. Novartis AG
• 16. Panacea Biotec Ltd.
• 17. Petrovax Pharm
• 18. Pfizer Inc.
• 19. Sanofi S.A.
• 20. Serum Institute of India Pvt. Ltd.
• 21. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
• 22. Sinovac Biotech Ltd.
• 23. SK bioscience
• 24. Taj Pharmaceuticals Limited
• 25. Vabiotech
• 26. Walvax Biotechnology Co., Ltd.